What: Shares of biopharmaceutical company Medivation (NASDAQ:MDVN) sank as much as 11% after rival Johnson & Johnson (NYSE:JNJ) announced it was purchasing Aragon Pharmaceuticals to get ahold of its experimental advanced prostate cancer drug, ARN-509.
So what: Johnson & Johnson has agreed to purchase Aragon for $650 million with the potential for up to $350 million in additional milestone payments. ARN-509 is a currently in mid-stage trials and is considered a potential rival to Medivation's metastatic prostate cancer drug, Xtandi. Weighing in on today's actions, Citigroup analyst Yaron Werber noted concerns for Medivation, but also opined that J&J's purchase of ARN-509 is likely an indication that it expects the prostate cancer market to expand with its own FDA-approved prostate cancer drug, Zytiga, also in the same space.
Now what: Personally, I'd call today's move lower a gross overreaction. ARN-509 still has plenty to prove in clinical trials, and it'll be years before it makes it to market. In the meantime, Xtandi was approved in the U.S. three months ahead of its PDUFA date, it received approval in Canada two weeks ago, and it gained a positive view from the European Medicine Agency's panel. There is plenty of room for growth from Xtandi over the coming years, especially with prostate cancer being the most-diagnosed cancer of them all in the U.S. In sum, I wouldn't let J&J's purchase change your investing thesis on the company.
Craving more input? Start by adding Medivation to your free and personalized watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool owns shares of, and recommends, Johnson & Johnson. It also owns shares of Citigroup. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.